The Era of CFTR Modulators: Improvements Made and Remaining Challenges

Overview

Journal Breathe (Sheff)

Specialty Pulmonary Medicine

Date 2020 Dec 11

PMID 33304402

Citations 19

Authors

Sara Cuevas-Ocana

Onofrio Laselva

Julie Avolio

Raffaella Nenna

Affiliations

Soon will be listed here.

Abstract

https://bit.ly/3aRafQF.

Citing Articles

Inhibiting CFTR through inh-172 in primary neutrophils reveals CFTR-specific functional defects.

Da Silva Cunha A, Blanter M, Renders J, Gouwy M, Lorent N, Boon M Sci Rep. 2024; 14(1):31237.

PMID: 39732786 PMC: 11682091. DOI: 10.1038/s41598-024-82535-z.

Identification of novel natural compounds against CFTR p.Gly628Arg pathogenic variant.

Khan M, Sakhawat A, Rehman R, Wali A, Ghani M, Akram A AMB Express. 2024; 14(1):99.

PMID: 39249658 PMC: 11383896. DOI: 10.1186/s13568-024-01762-9.

in chronic lung disease: untangling the dysregulated host immune response.

Nickerson R, Thornton C, Johnston B, Lee A, Cheng Z Front Immunol. 2024; 15:1405376.

PMID: 39015565 PMC: 11250099. DOI: 10.3389/fimmu.2024.1405376.

Cystic fibrosis management in pediatric population-from clinical features to personalized therapy.

Azoicai A, Lupu A, Trandafir L, Alexoae M, Alecsa M, Starcea I Front Pediatr. 2024; 12:1393193.

PMID: 38798310 PMC: 11116730. DOI: 10.3389/fped.2024.1393193.

Olive Leaf Extract (OLE) as a Novel Antioxidant That Ameliorates the Inflammatory Response in Cystic Fibrosis.

Allegretta C, Difonzo G, Caponio F, Tamma G, Laselva O Cells. 2023; 12(13).

PMID: 37443798 PMC: 10340374. DOI: 10.3390/cells12131764.

References

Valley H, Bukis K, Bell A, Cheng Y, Wong E, Jordan N . Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells. J Cyst Fibros. 2018; 18(4):476-483. DOI: 10.1016/j.jcf.2018.12.001. View

Paranjapye A, Ruffin M, Harris A, Corvol H . Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity. J Cyst Fibros. 2019; 19 Suppl 1:S10-S14. PMC: 7036019. DOI: 10.1016/j.jcf.2019.11.001. View

Sagel S, Wagner B, Ziady A, Kelley T, Clancy J, Narvaez-Rivas M . Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity. J Cyst Fibros. 2019; 19(4):632-640. PMC: 7305052. DOI: 10.1016/j.jcf.2019.12.007. View

Nick J, St Clair C, Jones M, Lan L, Higgins M . Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study. J Cyst Fibros. 2019; 19(1):91-98. DOI: 10.1016/j.jcf.2019.09.013. View

Kelly A, De Leon D, Sheikh S, Camburn D, Kubrak C, Peleckis A . Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy. Am J Respir Crit Care Med. 2018; 199(3):342-351. PMC: 6835076. DOI: 10.1164/rccm.201806-1018OC. View

Ramsey B, Davies J, McElvaney N, Tullis E, Bell S, Drevinek P . A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365(18):1663-72. PMC: 3230303. DOI: 10.1056/NEJMoa1105185. View

Laselva O, Marzaro G, Vaccarin C, Lampronti I, Tamanini A, Lippi G . Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators. Front Pharmacol. 2018; 9:719. PMC: 6039571. DOI: 10.3389/fphar.2018.00719. View

Trinh N, Bilodeau C, Maille E, Ruffin M, Quintal M, Desrosiers M . Deleterious impact of Pseudomonas aeruginosa on cystic fibrosis transmembrane conductance regulator function and rescue in airway epithelial cells. Eur Respir J. 2015; 45(6):1590-602. DOI: 10.1183/09031936.00076214. View

DeStefano S, Gees M, Hwang T . Physiological and pharmacological characterization of the N1303K mutant CFTR. J Cyst Fibros. 2018; 17(5):573-581. PMC: 7008954. DOI: 10.1016/j.jcf.2018.05.011. View

10.

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

11.

Aksit M, Pace R, Vecchio-Pagan B, Ling H, Rommens J, Boelle P . Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits. J Clin Endocrinol Metab. 2019; 105(5). PMC: 7236628. DOI: 10.1210/clinem/dgz102. View

12.

. Tezacaftor/ivacaftor for cystic fibrosis. Aust Prescr. 2019; 42(5):174-175. PMC: 6787300. DOI: 10.18773/austprescr.2019.060. View

13.

Eckford P, Ramjeesingh M, Molinski S, Pasyk S, Dekkers J, Li C . VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem Biol. 2014; 21(5):666-78. DOI: 10.1016/j.chembiol.2014.02.021. View

14.

Boelle P, Debray D, Guillot L, Clement A, Corvol H . Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology. 2018; 69(4):1648-1656. PMC: 6519059. DOI: 10.1002/hep.30148. View

15.

Laselva O, Eckford P, Bartlett C, Ouyang H, Gunawardena T, Gonska T . Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action. J Cyst Fibros. 2019; 19(5):717-727. DOI: 10.1016/j.jcf.2019.12.001. View

16.

Saiman L . Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy. Pediatr Pulmonol. 2019; 54 Suppl 3:S18-S26. DOI: 10.1002/ppul.24522. View

17.

Van Goor F, Yu H, Burton B, Hoffman B . Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2013; 13(1):29-36. DOI: 10.1016/j.jcf.2013.06.008. View

18.

Clancy J, Cotton C, Donaldson S, Solomon G, VanDevanter D, Boyle M . CFTR modulator theratyping: Current status, gaps and future directions. J Cyst Fibros. 2018; 18(1):22-34. PMC: 6301143. DOI: 10.1016/j.jcf.2018.05.004. View

19.

Sun X, Yi Y, Yan Z, Rosen B, Liang B, Winter M . In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis. Sci Transl Med. 2019; 11(485). PMC: 6489481. DOI: 10.1126/scitranslmed.aau7531. View

20.

Joshi D, Ehrhardt A, Hong J, Sorscher E . Cystic fibrosis precision therapeutics: Emerging considerations. Pediatr Pulmonol. 2019; 54 Suppl 3:S13-S17. PMC: 6871648. DOI: 10.1002/ppul.24547. View